Navigation Links
FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
Date:10/19/2010

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Atrial fibrillation, which affects more than 2 million Americans, involves very fast and uncoordinated contractions of the heart's two upper heart chambers (atria) and is one of the most common types of abnormal heart rhythm.

"People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research.

Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pradaxa with the anticoagulant warfarin. In the trial, patients taking Pradaxa had fewer strokes than those who took warfarin.

"Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," Stockbridge says.

As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, was among the most common adverse reactions reported by patients treated with Pradaxa. Gastrointestinal symptoms, including an uncomfortable feeling in the stomach (dyspepsia), stomach pain, nausea, heartburn, and bloating also were reported.

Pradaxa was approved with a Medication Guide that informs patients of the risk of serious bleeding. The guide will be distributed each time a patient fills a prescription for the medication.

Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. of Ridgefield, Conn., will be available in 75 milligram and 150 milligram capsules.

For more information:

National Heart, Lung, and Blood Institute – What is Atrial Fibrillation?

http://www.nhlbi.nih.gov/health/dci/Diseases/af/af_what.html

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Sandy Walsh, 301-796-4669; sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Botox to Treat Chronic Migraine
2. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
3. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
4. FDA Approves Combination Contraceptive Containing a Folate
5. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
6. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
7. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
8. FDA Approves Pediatric Use of Chemical Poisoning Treatment
9. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
10. FDA Approves Vaccines for the 2010-2011 Influenza Season
11. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Pfizer joins Astex, AstraZeneca, ... Consortium   Major research investment to ...   The Milner Therapeutics Institute today ... a partner to the Milner Therapeutics Consortium. Pfizer has ... transfer of materials between industry and academia and allocation ...
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... , Marks E-QURE , s ... following similar agreements in Israel and Argentina ... 5 billion global market ... in medical devices for the treatment of advanced wound care, announced today it ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate , founder of ... to the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with ... saw firsthand the effect of the critical funding gap for research into pediatric cancer ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Bill Howe Plumbing, ... with the American Heart Association; “Howe” Healthy is Your Heart Drawing Contest ... and active. Each year, Bill Howe Plumbing, Heating & Air receives over 600 entries. ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics is ... the editing process for all media productions," said Christina Austin - CEO of ... simplistically styled self-animating paragraphs designed for multi-lined text purposes. Choose from presets ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for building ... know that popular cosmetic fillers can enhance earlobes and rejuvenate an ... of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. “People ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating and ... , Certain Dri created this infographic to explain the seven types of hyperhidrosis. ...
Breaking Medicine News(10 mins):